Amelioration of accelerated collagen induced arthritis by a novel calcineurin inhibitor, ISATX247

Journal of Rheumatology

Volumn 29, Issue 8, 2002, Pages 1646-1652

  Maksymowych, Walter P ^a   Jhangri, Gian S ^a   Aspeslet, Launa ^a   Abel, Mark D ^a   Trepanier, Daniel J ^a   Naicker, Selvaraj ^a   Freitag, Derrick G ^a   Cooper, Bobbi Lynn ^a   Foster, Robert T ^a   Yatscoff, Randall W ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Calcineurin inhibitor; Collagen arthritis; Cyclosporine

Indexed keywords

CALCINEURIN INHIBITOR; COLLAGEN; CYCLOSPORIN A; ISATX 247; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; CALCINEURIN; COLLAGEN TYPE 2; CYCLOSPORIN; IMMUNOLOGICAL ADJUVANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; HISTOPATHOLOGY; MOUSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SCORING SYSTEM; ANIMAL; ARTICULAR CARTILAGE; DBA MOUSE; DISEASE MODEL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; HINDLIMB; IMMUNOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; JOINT; PATHOLOGY; PATHOPHYSIOLOGY; RANDOMIZATION; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ANIMAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, EXPERIMENTAL; CALCINEURIN; CARTILAGE, ARTICULAR; COLLAGEN TYPE II; CYCLOSPORINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HINDLIMB; INJECTIONS, INTRAPERITONEAL; JOINTS; MICE; MICE, INBRED DBA; RANDOM ALLOCATION; SUPPORT, NON-U.S. GOV'T; TREATMENT OUTCOME; ANIMALS;

EID: 0036021135     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Cytokines in autoimmune disorders
2. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis
3. Infliximab (chimeric anti-tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial
4. How important are T cells in chronic rheumatoid synovitis?
5. Production of cytokines and metalloproteinases in rheumatoid synovitis is T cell dependent
6. Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis
7. Chronic relapsing homologous collagen-induced arthritis in DBA/I mice as a model for testing disease-modifying and remission-inducing therapies
8. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis
9. Cyclosporin treatment for rheumatoid arthritis: A placebo controlled, double blind, multicentre study
10. Cyclosporin in rheumatoid arthritis: A double-blind, placebo-controlled study in 52 patients
11. Low dose cyclosporin in rheumatoid arthritis: A pilot study
12. Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine: Results of a 48-week multicenter study comparing low-dose cyclosporine with placebo
13. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis
14. Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin A
15. Effects of cyclosporine on joint damage in rheumatoid arthritis
16. Cyclosporine A in rheumatoid arthritis: Randomized, placebo controlled dose-finding study
17. Cyclosporine A specifically inhibits function of nuclear proteins involved in T cell activation
18. Nuclear association of a T-cell transcription factor blocked by FK506 and cyclosporin A
19. Effects of gold sodium thiomalate, cyclosporin A, cyclophosphamide, and placebo on collagen-induced arthritis in rats
20. Inhibition by FK506 of established lesions of collagen-induced arthritis in rats
21. Therapeutic actions of cyclosporine and anti-tumor necrosis factor alpha in collageninduced arthritis and the effect of combination therapy
22. Alternative cyclosporine metabolic pathways and toxicity
23. TX247
24. TX247, a novel calcineurin inhibitor
25. TX247
26. TX247: A novel calcineurin inhibitor with minimal renal toxicity
27. Bacterial lipopolysaccharide potentiates type II collagen-induced arthritis in mice
28. Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: Requirement for both B7-1 and B7-2
29. Pathogenesis of rheumatoid arthritis: The role of T cells and other beasts
30. TX247 on whole blood lymphocytes of nonhuman primates
31. TX247, a novel calcineurin inhibitor
32. TX247: Phase 1 clinical trial results of the novel calcineurin inhibitor
33. Cyclosporine and tacrolimus (FK506): A comparison of efficacy and safety profiles
34. Point mutations in v-Myb disrupt a cyclophilin-catalyzed negative regulatory mechanism
35. Cyclosporin A potentiates the dexamethasone-induced mouse mammary tumor virus-chloramphenicol acetyltransferase activity in LMCAT cells: A possible role for different heat shock protein-binding immunophilins in glucocorticosteroid receptor-mediated gene expression
36. Immunosuppressants: Cellular and molecular mechanisms of action
37. Effect of cyclosporin A and analogues on cytosolic calcium and vasoconstriction: Possible lack of relationship to immunosuppressive activity
38. Chronic rejection and chronic cyclosporin toxicity in renal allografts
39. Differential subcellular localization of neural isoforms of the catalytic subunit of calmodulin-dependent protein phosphatase (calcineurin) in central nervous system neurons: Immunohistochemistry on formalin-fixed paraffin sections employing antigen retrieval by microwave irradiation
40. FKBP12-FK506 complex inhibits phosphatase activity of two mammalian isoforms of calcineurin irrespective of their subtrates or activation mechanisms
41. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
42. Immunosuppressive properties of methotrexate: Apoptosis and clonal deletion of activated peripheral T cells